J. E. Bowman

Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients.

S. Gerson, J. Reese, Karen T. Lingas, 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

Cancer gene therapy: scientific basis.

S. Gerson, S. Zielske, C. Ballas, 2002, Annual review of medicine.